Facebook
Twitter
LinkedIn
ForwardMGH Cancer Center Grand Rounds 2022-2023: Archived
Description
This activity provides on-demand archived lectures from the MGH Cancer Center Grand Rounds 2022-2023 series. As one of the leading academic cancer centers in the country, our research and clinical staff need to be educated on cutting edge information on advances and perspectives on cancer research and treatment across the full spectrum of cancer specialization. This will help clinicians understand, assess and apply this information in our rapidly advancing and highly specialized organization. Clinicians will present and discuss this information in a multi-specialty setting. Clinicians will be informed and challenged across the organization to reach beyond their own specialization and role, and support higher levels of learning and competence for themselves, teams, and functions.
Session formats will vary between didactic presentations, panel discussions, and debates. All sessions will allow live attendees the opportunity to interact with the presenters and ask questions, thus supporting active learning.
Course Director: Colin D. Weekes, MD, PhD
For questions regarding the registration process, please contact Mass General Brigham Office of Continuing Professional Development at partnerscpd@partners.org.
You may print individual certificates throughout the year; your cumulative list of sessions attended is accessible on your transcript.
This session will broadcast outside of Mass General Brigham
Target Audience
This activity is intended for medical professionals in the field of oncology.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Evaluate recent advances or controversies in hematology/oncology treatment, clinical research and/or basic science investigation presented in this conference
- Assess opportunities to integrate information, tools or practices presented in this conference into how you deliver or support research and patient care
- Incorporate new information or perspectives from this conference into specific aspects of your responsibilities in patient care, research or the system in which you work
- Recognize evolving landscape of cancer care worldwide
Additional Information
Mass General Brigham
Schedule:
Date | Subject | Speaker |
September 15, 2022 | Leveraging Opportunities to Facilitate Inclusive Cancer Drug Development | Lola Fashoyin-Aje, MD, MPH |
October 6, 2022 | Extending Immunotherapy Combinations in Gastroesophageal Cancer: How, What and When? | Ian Chau, MD, FRCP |
October 13, 2022 | New Considerations for Immunotherapy in Sarcoma | Seth M. Pollack, MD |
October 27, 2022 | Kidney Cancer: Bench to Bedside and Back | James Brugarolas, MD, PhD |
November 3, 2022 | Debate: Adjuvant/Neoadjuvant Immune Checkpoint Inhibitor Therapy | Rodabe Amaria, MD |
November 10, 2022 | TLR9 Agonists in Melanoma and Other Cancers: Current Development, Next Steps | Diwakar Davar, MD |
December 1, 2022 | The Chabner Pioneers in Oncology Lectureship: Translating Aging Biology Into Patient Care | Norman Sharpless, MD |
Course Director
Colin D. Weekes, MD, PhD
Director, Pancreatic Cancer Research,
Mass General Cancer Center;
Associate Professor of Medicine,
Harvard Medical School
Disclosure Summary of Relevant Financial Relationships
INELIGIBLE COMPANIES
Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
For more information: https://accme.org/faq/what-accmes-definition-ineligible-company
MITIGATION STRATEGIES
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.
The following planners reported no relevant financial relationship with an ineligible company:
Colin D. Weekes, MD, MPH
ACCREDITATION
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA PRA Category 1 CreditTM
Mass General Brigham designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.